References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
- Papaccio F, Paino F, Regad T, et al. Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med. 2017;6:2115–2125.
- Wedenoja S, Yoshihara M, Teder H, et al. Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia [published online ahead of print, 2020 Jul 11]. EBioMedicine. 2020;59:102872.
- Ferreira LMR, Meer TB, Tilburgs T, et al. HLA-G: at the interface of maternal-fetal tolerance. Trends Immunol. 2017;38:272–286.
- Cirulli V, Zalatan J, McMaster M, et al. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes.2006;55:1214–1222.
- Le Discorde M, Moreau P, Sabatier P, et al. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol. 2003;64:1039–1044.
- González A, Rebmann V, LeMaoult J, et al. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci2012;49:63–84.
- Carosella ED, Gregori S, LeMaoult J. The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells. Blood. 2011;118:6499–6505.
- Lin A, Yan WH. Human Leukocyte Antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med. 2015;21:782–791.
- Jiang Y, Lu J, Wu YE, et al. Genetic variation in the HLA-G 3ʹUTR 14-bp insertion/deletion and the associated cancer risk: evidence from 25 case-control studies. Biosci Rep. 2019 Published 2019 May 10;39:BSR20181991.
- Rousseau P, Le Discorde M, Mouillot G, et al. The 14 bp deletion-insertion polymorphism in the 3ʹ UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol. 2003;64:1005–1010.
- Krijgsman D, Roelands J, Hendrickx W, et al. HLA-G: a new immune checkpoint in cancer? Int J Mol Sci. 2020 Published 2020 Jun 25;21:4528.
- Castelli EC, Moreau P. Oya e Chiromatzo A, et al. In silico analysis of microRNAS targeting the HLA-G 3ʹ untranslated region alleles and haplotypes. Hum Immunol. 2009;70:1020–1025.
- Ouni N, Chaaben AB, Kablouti G, et al. The impact of HLA-G 3ʹUTR polymorphisms in breast cancer in a Tunisian population. Immunol Invest. 2019;48:521–532.
- Schwich E, Rebmann V, Michita RT, et al. HLA-G 3ʹ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer. Sci Rep. 2019;9:5407.
- Castelli EC, Ramalho J, Porto IO, et al. Insights into HLA-G genetics provided by worldwide haplotype diversity. Front Immunol. 2014;5:476.